Seeking a Population That Derives a Significant Benefit From Prasugrel

Harlan M. Krumholz, MD, SM

Disclosures

Journal Watch 

In This Article

Comment

In this trial, greater platelet inhibition with prasugrel than with clopidogrel did not translate into a discernible benefit in patients with acute coronary syndromes who did not undergo revascularization. The lower-cost agent was as good as the higher-cost one.

processing....